Skip to main content
Premium Trial:

Request an Annual Quote

Agile Biodetection Licenses SARS-CoV-2 Detection Tech From Harvard Wyss Institute

NEW YORK – Harvard's Wyss Institute for Biologically Inspired Engineering announced Monday its nasopharyngeal swab and toehold switch technologies have been licensed by Agile Biodetection to develop diagnostic solutions for SARS-CoV-2. 

Harvard's Office of Technology coordinated the non-exclusive, royalty-free licensing agreement, which allows Agile to detect SARS-CoV-2 in environmental or clinical settings. The agreement is a part of the COVID-19 Technology Access Framework, started by Harvard, to "incentivize the rapid utilization of available technologies that can facilitate the diagnosis, treatment, and prevention" of SARS-CoV-2, the university said. 

The Wyss Institute's nasopharyngeal swabs were developed in response to the global swab shortage during the COVID-19 pandemic and are fully injection-molded from one material. The swabs can be mass manufactured in one step, making them faster and cheaper to produce, and were "demonstrated to effectively collect" SARS-CoV-2 material from patients more comfortably than other products, the institute said in a statement.

The synthetic nucleic acid-based toehold switches act as sensors for external stimuli, such as RNA molecules, the institute said. They can be integrated into synthetic gene circuits to turn on a gene of interest and function in living cells as computational devices that can report environmental stimuli. When they are turned off, the toehold switches block the expression of a target gene until the input RNA binds to their toehold region, allowing for synthesis of the signaling molecule.

Researchers have also utilized toehold switches for paper-based synthetic gene circuits for infectious diseases. They have high sensitivity and specificity and can be used to monitor the presence of pathogens in a variety of environments, the institute added. 

Birmingham, Alabama-based Agile Biodetection is focused on detecting SARS-CoV-2 in the environment, instead of testing patients for the virus, looking at surfaces and touchpoints in high-traffic areas. The firm also has a high-throughput cloud-based system to distribute the testing results.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.